← Russell 3000 cross-section

OABI OmniAb, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$674m
Revenue TTM
$38m
Net income TTM
$-44m
Free cash flow
$-18m
Composite score
49.3
Sector rank
#2248

Valuation

P / E
EV / EBITDA
EV / sales
16.2
FCF yield
-2.69%
Earnings yield vs 10-yr
-11.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-115.1%
EBITDA margin
-66.9%
ROE
-17.0%
ROIC
-23.2%
Revenue growth
67.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments. We believe our revenue will be materially driven by milestones and services in the shorter term, and by royalties in the longer term, from our partnered programs. The Sales Agent will receive a commission from us of up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement.OmniAb, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →